MicroPort<sup>®</sup> Attends CCIF 2018

Yinchuan, China – From April 19 to April 22, Shanghai MicroPort Medical (Group) Co. Ltd. ("MicroPort®") attended the 21th China Cardiovascular Interventional Forum ("CCIF 2018") and hosted a case contest. With thousands of domestic and overseas cardiologists in attendance, the CCIF 2018 aims at promoting the new advancement of China's interventional cardiology and sharing the new philosophy, new technology and new method of interventional cardiology.
 
During the congress, the CCIF President Professor Yong Huo of Peking University First Hospital released the registration data of coronary heart disease interventional treatment in the Chinese mainland in 2017. According to the data, the total number of such treatment stood at 753,142 in 2017. Professor Huo said, the number experienced steady increase in 2017; on average 1.5 stents were used in each case, which remained unchanged from the previous years; the death rate of interventional treatment remained low; the percentage of radial artery approach continued to go up, showing that more physicians can master the technique; the percentage of PCI treatment of STEMI patients further increased, showing the effect of building more Chest Pain Centers; physicians in the district hospitals are playing an increasingly important role in coronary heart disease treatment with their enhanced PCI surgical skill.
 
On April 21, MicroPort® hosted a case contest with 14 cases involved in. Professor Guosheng Fu of Sir Run Run Shaw of Zhejiang University School of Medicine, Professor Lianglong Chen of Fujian Medical University Union Hospital, Professor Lang Hong of Jiangxi Provincial People's Hospital, and Professor Lixia Yang of Chengdu Military General Hospital were invited as moderators. In the end, Professor Xinyong Cai of Jiangxi Provincial People's Hospital, Professor Hanbin Cui of Ningbo First Hospital, and Professor Bing Duan of Shijiazhuang First Hospital won the first place. Meanwhile, this case competition was live broadcasted via Dr. King studio and MicroPort® online platform, which attracted more than 1,500 audience to watch online. It provided opportunities for physicians in rural areas to learn more advanced technologies.
 
Since 2016, MicroPort® hosted the case competition in various national-level congresses and has received positive feedback. It was the third time for MicroPort® to host such seminar in the CCIF, which fully demonstrated the excellent performance of its stents. Meanwhile, MicroPort® also carried out satisfaction survey activities during the conference. Experts showed high recognition of MicroPort®'s cardiovascular products such as Firehawk® and Firebird2®, and offered suggestions regarding product R&D.